Novo Nordisk A/S has received a positive opinion from the European Medicines Agency (EMA) for its new treatment for haemophilia B, a genetic disorder caused by missing or defective factor IX, a blood clotting protein. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
